31 January 2025 - Recommendations made by the PBAC in December 2024 relating to the listing of medicines on the PBS ...
30 January 2025 - A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within ...
30 January 2025 - Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class ...
16 January 2025 - The rare muscle wasting disorder affects approximately 2,500 males in the UK at any one time. ...
28 January 2025 - The approval is based on the results of the pivotal FLOW Phase 3b kidney outcomes trial and ...
13 January 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
27 January 2025 - Apellis Pharmaceuticals announced today that the TGA has approved Syfovre (pegcetacoplan) for the every-other-month treatment of adult ...
27 January 2025 - Based on DESTINY-Breast06 phase 3 trial results which showed Enhertu demonstrated superiority versus chemotherapy with a ...
26 January 2025 - Once every four weeks maintenance dosing may be easier for patients and care partners to continue ...
24 January 2025 - The MHRA has today approved garadacimab (Andembry) for patients aged 12 years and older with hereditary angioedema ...
24 January 2025 - This regulatory approval for registration in Australia is the first in the world for Andembry. ...
23 January 2025 - NICE has published final evidence-based recommendations on the use of vadadustat (Vafseo) for the treatment of ...
22 January 2025 - Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed ...
22 January 2025 - Approval is based on positive results from the IMROZ Phase 3 study, demonstrating Sarclisa in combination with ...
21 January 2025 - We have also recommended osimertinib for routine use on the NHS today. ...